Printed From BioPortfolio.com

FDA Approves Nanobiotix’s First Immuno-Oncology Trial

06:05 EST 27 Dec 2017 | Pharmaceutical Processing

News

The multi-arm trial targets a sub-population of advanced and metastatic lung and head & neck cancer patients. NBTXR3 is an injectable aqueous suspension of hafnium oxide nanoparticles designed for direct injection into cancerous tumors.

Contributed Author:

Nanobiotix

Topics:

Drug Development

Original Article: FDA Approves Nanobiotix’s First Immuno-Oncology Trial

More From BioPortfolio on "FDA Approves Nanobiotix’s First Immuno-Oncology Trial"

Quick Links
Advanced Search | Login | Subscribe | RSS

Quick Search

Relevant Topics

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers) - Mouth cancer can develop on the lip, the tongue, the floor...

News Quicklinks

Search Biotech, Medical and Healthcare News

Biotech News by Article Type

BioPortfolio Bloggers

Publishing Your News on BioPortfolio

Recent Visitor News Searches